All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-04-10.
From the record
Guardant Health, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2023-04-10) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+45.1% a year over 9 filed years; profitable in 0 of 9.
From the record
Guardant Health, Inc.'s 9 filed years say what it did: revenue went from $50 million in fiscal 2017 to $982 million in fiscal 2025, up 45.1% a year; it rose in 8 of 8 years; it never fell from a peak; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Guardant Health, Inc.'s shareholder treatment is put at 5.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 43% of 24 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 105%: owes 105¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Guardant Health, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 31 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 105 cents per dollar of assets, and net share issuance: its share count grew 2.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 45% of 24 in its family; net margin -42.4%.
From the record
Guardant Health, Inc.'s standing among 24 graded names in its industry family: revenue of $982 million in fiscal 2025 ranks in the top 20% by size; a net margin of -42.4% ranks in the bottom 23%; revenue growth of 29.7% a year over the last 3 filed years ranks in the top 37% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 42% of 17 in its family for leadership; chief executive since 2021.
From the record
Guardant Health, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Talasaz, Amirali (Co-Chief Executive Officer, as filed), filing under that title since 2021-08-17, 5.2 years (top 44% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 5 years (bottom 37%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (bottom 34%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 44% of 24 in its family for room to expand.
From the record
Guardant Health, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $489 million against debt of $1.5 billion leaves -50.4% of its assets as net cash, bottom 2% of its family; cash from operations less capital spending is -23.7% of revenue (bottom 40%); a gross margin of 64.5% (top 34%); research spending of 37.1% of revenue (top 31%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 47% of 23 in its family for growth drivers.
From the record
Guardant Health, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 29.7% a year over the last three filed years against 45.1% over all 9, slowing (bottom 33% of its family); the newest year grew 32.9% (top 20%); research spending grew -0.9% a year (top 42%); capital spending grew -14.6% a year (bottom 40%) (its annual reports). Guardant Health, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 34% of 20 in its family for expectations against reality.
From the record
Guardant Health, Inc.'s newest year against its own record: revenue of $982 million in fiscal 2025 came in 3.7% above the $947 million its prior three years' pace pointed to (top 32% of its family); net income of $416 million against a prior three-year average of $523 million (top 42%); a net margin of -42.4% against -96.6% before (top 27%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made